Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss

1. Sage Therapeutics is a pharmaceutical company developing dalzanemdor, a potential therapeutic candidate.
2. The stakes for Sage's dalzanemdor readouts have been raised following a "Parkinson's miss".
3. The term "miss" in this context likely refers to a setback or unsuccessful clinical trial outcome related to Parkinson's disease.
4. The news article from FirstWord Pharma, while not directly providing details about the Parkinson's miss, suggests that the outcomes of dalzanemdor readouts are now under increased scrutiny.

Please note that the search results provided do not offer specific details about the Parkinson's miss or the dalzanemdor readouts. For more information, it would be necessary to consult additional sources or wait for official announcements from Sage Therapeutics.